Plasma lipoprotein composition, apolipoprotein(a) concentration and isoforms in beta-thalassemia

Atherosclerosis. 1997 May;131(1):127-33. doi: 10.1016/s0021-9150(97)06095-4.

Abstract

Patients with homozygous beta-thalassemia show an abnormal lipoprotein profile. In asymptomatic heterozygotes the lipid pattern is less markedly affected but interestingly related to a diminished cardiovascular risk. The extent and significance of these findings are still a matter of debate and no data are available on lipoprotein(a) plasma levels. Seventy patients with homozygous beta-thalassemia (HT-P), 70 beta-thalassemia trait carriers (TT-C) and 70 sex and age-matched controls were investigated and their plasma lipoprotein profile and apo(a) phenotypes determined. In a subgroup of these same subjects (12 HT-P, 12 TT-C and 24 controls) and in 12 bone marrow-transplanted homozygous beta-thalassemic patients (BMT-P) plasma lipoprotein composition was assessed. HT-P disclosed significantly lower total-cholesterol, LDL-cholesterol, HDL-cholesterol, apo A-I, apo B plasma levels and higher triglyceride concentration than TT-C (-7, -11, -8, -8, -13 and +11%, respectively) or controls (-39, -50, -46, -32, -30 and + 35%, respectively). All lipoprotein subclasses were triglyceride-enriched, while LDLs were also protein-enriched and HDLs protein-depleted. TT-C disclosed a small but significant reduction in apo A-I and apo B plasma levels but only minor lipoprotein abnormalities with respect to the controls. BMT-P lipoprotein composition was intermediate between HT-P and normal subjects. Apo(a) plasma levels did not differ among the groups. A higher prevalence of 'small' apo(a) isoforms was present in HT-P. Within the same 'isoform group', apo(a) plasma levels were significantly lower in HT-P than in TT-C or controls. Since liver cirrhosis is almost always present in HT-P, it is conceivable that an altered hepatic apo(a) synthesis or catabolism due perhaps to diminished apolipoprotein glycation may be involved. In TT-C a partially improved cardiovascular risk profile was apparent (low hematocrit, low LDL-cholesterol and apo B), thus justifying the claim for a low prevalence of ischemic heart disease, but no Lp(a) plasma level modification could be detected.

MeSH terms

  • Adolescent
  • Adult
  • Apolipoprotein A-I / metabolism
  • Apolipoproteins A / metabolism*
  • Apolipoproteins B / blood
  • Bone Marrow Transplantation
  • Cholesterol / blood
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Female
  • Heterozygote
  • Homozygote
  • Humans
  • Lipoproteins / blood*
  • Lipoproteins, HDL / blood
  • Lipoproteins, LDL / blood
  • Male
  • Triglycerides / blood
  • beta-Thalassemia / blood*
  • beta-Thalassemia / therapy

Substances

  • Apolipoprotein A-I
  • Apolipoproteins A
  • Apolipoproteins B
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Lipoproteins
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Triglycerides
  • Cholesterol